Michael P. Cooreman
Chief Tech/Sci/R&D Officer chez INVENTIVA
Fortune : 53 784 $ au 31/03/2024
Profil
Michael P.
Cooreman is currently the Chief Medical Officer at Inventiva SA since 2020.
Prior to this, he was the Vice President-Science & Medicine at Ferring Pharmaceuticals, Inc. from 2017 to 2020 and the Chief Medical Officer at ImmusanT, Inc. from 2015 to 2017.
He holds a doctorate degree from Heinrich-Heine-Universität Düsseldorf and Université Catholique de Louvain.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
INVENTIVA SA
0,03% | 01/03/2024 | 15 000 ( 0,03% ) | 53 784 $ | 31/03/2024 |
Postes actifs de Michael P. Cooreman
Sociétés | Poste | Début |
---|---|---|
INVENTIVA | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Anciens postes connus de Michael P. Cooreman
Sociétés | Poste | Fin |
---|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | 01/01/2020 |
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Formation de Michael P. Cooreman
Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Université Catholique de Louvain | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
INVENTIVA | Health Technology |
Entreprise privées | 2 |
---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |